Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.

Trial Details

NCT ID
NCT06961617
Phase
PHASE1
Sponsor
Lion TCR Pte. Ltd.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • LioCyx-M, HBV antigen-specific TCR-redirected T cells
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • HCC diagnosis confirmed by histology/ cytology or clinically
  • HCC that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
  • Has failed at least one line of systemic therapy for HCC
  • ECOG performance status ≤1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →